Development of Topical Delivery Systems for Flightless Neutralizing Antibody

Area of Science:

• Dermatology
• Biotechnology
• Wound Healing Research

Background:

• Flightless I (Flii) is a key actin remodeling protein regulating cellular functions crucial for wound repair.
• Flii has been identified as a therapeutic target for enhancing wound healing processes.
• Flii neutralizing antibodies (FnAb) have shown efficacy in vivo, but require optimized delivery.

Purpose of the Study:

• To develop and characterize an optimized topical delivery system for FnAb.
• To evaluate the stability, release kinetics, and skin penetration of FnAb formulations.
• To assess the efficacy of topical FnAb in reducing Flii expression in the epidermis.

Main Methods:

• Development and stability testing of three topical FnAb formulations.
• In vitro release studies to determine sustained release profiles.
• Ex vivo penetration studies using intact porcine skin.
• Immunohistochemical analysis to quantify Flii expression post-treatment.

Main Results:

• Three stable topical formulations of FnAb were successfully developed.
• All formulations demonstrated prolonged and sustained in vitro release of FnAb.
• FnAb successfully penetrated porcine epidermis and upper dermis.
• Topical FnAb significantly reduced epidermal Flii expression compared to controls.

Conclusions:

• An optimized topical delivery system for FnAb has been successfully developed.
• This system facilitates localized delivery, sustained release, and epidermal penetration of FnAb.
• The developed topical FnAb platform holds potential for future localized wound treatment strategies.